Sanofi closed 2025 with a strong fourth quarter: net sales rose 13.3% at constant exchange rates to €11.3 billion and business EPS advanced 26.7% to €1.53. Dupixent delivered a powerful finish, with quarterly sales up 32.2% to €4.2 billion, while recent pharma launches nearly doubled to €1.1 billion, led by Ayvakit and Altuviiio. Vaccines declined 2.5% to €2.0 billion despite better-than-expected influenza demand. For the year, sales reached €43.6 billion, up 9.9% at constant exchange rates, with business EPS up 15.0% to €7.83. Sanofi paired the results with pipeline momentum across immunology and rare diseases, a pending acquisition of Dynavax, completion of the Vicebio acquisition, a €5 billion buyback already executed, and a proposed dividend increase. Guidance for 2026 calls for high–single-digit sales growth at constant exchange rates and business EPS growing slightly faster, supported by an additional €1 billion share repurchase.
The performance underscores a strategic reality: Sanofi has become an immunology and specialty medicine company first, vaccines second, and everything else at a distance. That concentration is an asset and a risk. Dupixent remains the defining growth engine, but the company is moving quickly to backfill and diversify with amlitelimab in atopic dermatitis, additional Dupixent indications, and a refreshed vaccines strategy catalyzed by Dynavax’s adjuvant platform. The quarter’s negative IFRS EPS and the tolebrutinib miss in primary progressive MS suggest active portfolio pruning and non-cash charges tied to pipeline resets—an acceptable cost if capital is recycled into higher-probability, higher-return assets.
For payers and health systems, the message is a continued shift of budget toward high-value specialty immunology. Dupixent’s expansion into new Type 2 and respiratory settings, coupled with amlitelimab’s late-stage progress, will intensify formulary pressure and raise evidence thresholds. Sanofi’s agreement with the U.S. government to lower medicine costs signals an accommodation to evolving price controls and negotiation regimes; Medical Affairs will need robust real-world data packages to sustain access, justify step edits, and address adherence outside controlled trials. For HCPs, the portfolio suggests broader options across dermatitis and allergic pathways, but also more complex patient segmentation and treatment sequencing.
On vaccines, the Dynavax deal—anchored by CpG 1018 and commercial HEPLISAV-B—positions Sanofi to retool adult immunization with adjuvant-enabled durability and speed, while Vicebio augments the protein-based respiratory pipeline. The near-term dip in vaccines revenue, despite influenza outperformance, heightens the imperative to convert platform assets into differentiated launches in RSV, next-gen influenza, and pandemic readiness. Competitively, this is a direct shot across the bows of GSK and Pfizer in respiratory and of emergent mRNA incumbents, with adjuvant science as the wedge for differentiation in efficacy, durability, and supply scalability.
Industry-wide, the playbook is familiar yet evolving: concentrate capital in durable immunology franchises, augment with cash-generative platform acquisitions rather than binary early science, and return surplus cash through buybacks and dividends. The BTK setback in PPMS reinforces the value of mechanism diversity and de-risks Sanofi’s tilt toward pathways with validated inflammatory biology. The open question for 2026 is whether amlitelimab and the vaccines reboot can meaningfully reduce Sanofi’s dependence on Dupixent just as pricing pressure intensifies in major markets. If the Dynavax integration accelerates a differentiated adjuvant stack and amlitelimab sustains Phase 3 momentum, Sanofi could convert a strong quarter into a more resilient growth algorithm; if not, the company risks being a single-engine growth story in a tougher pricing climate.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
